Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Dietrich Alexander Ruess

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4371-2246; OpenAlex author ID A5051714577. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 4 papers · 2026: 5 papers

Papers 19

  1. Experimental evaluation of an intraoperative-imaging based workflow for electron beam radiotherapy of pancreatic cancer using in situ dosimetry. Co-author DOI 10.1002/acm2.70556↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Last author DOI 10.1038/s41392-025-02563-7↗
  4. Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer Last author DOI 10.64898/2026.05.23.727401↗
  5. Improvement of Gemcitabine Treatment of Pancreatic Cancer by the Addition of All- trans Retinoic Acid and Identification of Vitamin A and Pentraxin 3 as Potent… Co-author DOI 10.64898/2026.08.16.26359923↗
  6. 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. Last author DOI 10.1002/jmri.29589↗
  7. The distance to arteries predicts the oncological outcome in pancreatic cancer surgery - results from a 3D reconstruction model. Co-author DOI 10.1016/j.pan.2025.09.024↗
  8. Adaptive resistance to SHP2-based vertical RAS-pathway inhibition in pancreatic cancer involves multifaceted routes towards dedifferentiation Last author DOI 10.1101/2025.09.09.25335395↗
  9. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  10. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2022.100815↗
  11. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. First author DOI 10.3390/cancers14235926↗
  12. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-021-86779-x↗
  13. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  14. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? First author DOI 10.3390/biomedicines8080281↗
  15. NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. First author DOI 10.3390/cancers11070937↗
  16. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Co-author DOI 10.3389/fimmu.2018.01878↗
  17. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Co-author DOI 10.1007/s40266-017-0453-y↗
  18. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  19. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12893-015-0110-5↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wilfried Reichardt · 4 shared papers, 2025–2026 · strength 0.85
  2. Asma Y. Alrawashdeh · 4 shared papers, 2025–2026 · strength 0.85
  3. Philipp Hafner · 4 shared papers, 2025–2026 · strength 0.85
  4. Melanie Boerries · 4 shared papers, 2025–2026 · strength 0.84
  5. Hana Algül · 7 shared papers, 2017–2025 · strength 0.77
  6. Uwe A. Wittel · 4 shared papers, 2015–2026 · strength 0.66
  7. Sophia Chikhladze · 3 shared papers, 2015–2026 · strength 0.54
  8. Carola Focke · 2 shared papers, 2025–2026 · strength 0.49
  9. Kıvanç Görgülü · 4 shared papers, 2017–2025 · strength 0.46
  10. Derya Kabacaoğlu · 4 shared papers, 2018–2022 · strength 0.46
  11. Friederike Inga Nollmann · 2 shared papers, 2020–2026 · strength 0.44
  12. Xun Chen · 2 shared papers, 2025 · strength 0.42
  13. Heiko Becker · 2 shared papers, 2022–2026 · strength 0.42
  14. Michael Quante · 2 shared papers, 2022–2026 · strength 0.42
  15. Marina Lesina · 4 shared papers, 2017–2025 · strength 0.41
  16. Jiaoyu Ai · 3 shared papers, 2019–2025 · strength 0.39
  17. Bruno Sáinz · 3 shared papers, 2021–2025 · strength 0.36
  18. Dimos Baltas · 1 shared paper, 2026 · strength 0.30
  19. Charoula Iliaskou · 1 shared paper, 2026 · strength 0.30
  20. Katrin J. Frank · 2 shared papers, 2022–2025 · strength 0.28
  21. Sonia Alcalá · 2 shared papers, 2021–2025 · strength 0.25
  22. Roland Michael Schmid · 2 shared papers, 2021–2025 · strength 0.25
  23. İhsan Ekin Demir · 2 shared papers, 2021–2025 · strength 0.25
  24. Sarah Niessen · 1 shared paper, 2026 · strength 0.22
  25. Katrin J. Ciecielski · 2 shared papers, 2018–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.